<DOC>
	<DOCNO>NCT01066897</DOCNO>
	<brief_summary>We hope learn brain circuit important understanding depression , anhedonia positive affect responds novel pharmaceutical treatment depression relate symptom . Adults diagnosis major depression completely responsive antidepressant medication seek participation ; equal number adult suffer disorder . Those suffer depression give pramipexole , investigational medication eight week information collect mood , cognition , brain function . Adults suffer depression also evaluate measure .</brief_summary>
	<brief_title>Imaging Nucleus Accumbens Major Depressed Patients 'Treated With Pramipexole</brief_title>
	<detailed_description>Patients meet DSM-IV criterion major depression ( use SCID ) , Hamilton Depression Rating Scale score least 18 , complete responder antidepressant medication invite participate open label study pramipexole . Patients complete responder adequate trial antidepressant ( see inclusion criterion ) openly treat pramipexole 8 week . Participants must age 20-55 include men woman . Patient 's mood assess visit use Hamilton Depression ( HDRS ) also complete series questionnaire . This include physical social anhedonia scale ( Chapman et al. , 1976 ; Eckblad et al. , 1982 ) , Snaith-Hamilton Pleasure Scale ( SHAPS ; Franken et al. , 2007 ; Snaith et al. , 1995 ) , Mood Anxiety Symptom Questionnaire Short Form ( MASQ ; Watson , Weber , et al. , 1995 ; Watson , Clark , et al. , 1995 ) , Positive Negative Affect Scale ( Watson &amp; Clark , 1991 ) among others . No adjunctive agent allow eight week study . Patients see four week weekly basis , biweekly thereafter . Patients receive 0.125 mg pramipexole three time day first week , 0.25 mg three time day second week , 0.5 mg three time day third week . The dose adjust need treat physician ( Dr. DeBattista ) , target range 1.0 mg 1.5 mg per day . Dose escalation continue 1 ) achievement primary endpoint ( &gt; 50 % reduction baseline HDRS score ; 2 ) intolerable side effect ; 3 ) completion 8-week study . Participants see weekly first four week biweekly thereafter . Side effect , depression , anhedonia assess visit . Depressed participant also undergo functional MRI neuropsychological testing twice , baseline completion medication . 20 healthy control subject history Axis I disorder score less 5 HDRS participate baseline MRI , neuropsychological testing , clinical ratings/questionnaires .</detailed_description>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Must meet DSMIV criterion Major Depressive Disorder 2 . HAMD score &gt; 18 21item assessment eligibility 3 . On least adequate dose fluoxetine ( 40 mg/day ) , paroxetine ( 40 mg/day ) paroxetine CR ( 50mg ) , sertraline ( 150 mg/day ) , citalopram ( 40 mg/day ) , escitalopram ( 20 mg/day ) , venlafaxine ( 150 mg/day ) , mirtazapine ( 30 mg/day ) , duloxetine ( 60 mg/day ) least 6 week ( monotherapy ) . 4 . 2055 year age 1 . Substance abuse past 6 month 2 . ECT past 6 month 3 . On MAOI , tricyclic antidepressant , lithium , antipsychotic , thyroid augmentation , 2 antidepressant simultaneously lamotrigine 4 . History psychosis include psychotic depression 5 . History Bipolar I , Bipolar II , Bipolar NOS illness , concurrent symptom mania hypomania meet criterion bipolar disorder 6 . History compulsive gamble 7 . Pregnant female female childbearing year use adequate birth control opinion investigator 8 . Known sensitivity Pramipexole 9 . Significant suicide risk opinion investigator 10 . Significant medical condition would preclude safe participation study opinion investigator 11 . Psychoactive drug one antidepressant list Inclusion criterion # 4 . ( A nonbarbiturate sedative hypnotic benzodiazepine trazodone 50mg/day , zolpidem 10mg/day , lorazepam 3mg/day clonazepam 2mg/day allow use least 1 month prior baseline visit . ) 12 . Significant abnormality observe screen laboratory evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>